Nov 2026· Advancement of science· 0 citations· 55 references
Medicine
TL;DR
This work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.
Abstract
ABSTRACT The global epidemic of metabolic dysfunction‐associated steatohepatitis (MASH) is escalating without effective therapies. This study identified a significant depletion of the gut commensal bacterium Faecalibacterium duncaniae (F. duncaniae) as a core feature of MASH. To overcome the poor colonization by traditional probiotics in inflammatory environments, we engineered a living microbial therapeutic by incorporating chiral gold nanozymes onto F. duncaniae. We discovered that biological performance is enantiomer‐dependent: the right‐handed nanozyme (D‐Au) serves as a superior ROS‐scavenging shield, protecting the probiotic from oxidative assault and enhancing its colonization in the inflamed gut. In mouse models of MASH, this engineered probiotic (F@D‐Au) reversed disease progression, ameliorating steatosis, inflammation, and fibrosis. It further restored systemic homeostasis, rectifying dysbiosis, metabolic disturbances, and—notably—MASH‐associated cognitive impairment. Metabolomic analyses revealed that this multi‐organ benefit was linked to the restoration of key microbial metabolites, including kynurenic acid and linoleic acid. Our work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.
ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) currently lacks effective targeted therapeutics, while interleukin‐22 (IL‐22) as a potential treatment approach faces challenges in the clinical translation due to off‐target risks associated with systemic delivery. To address this limitation, we develope...
C. Ji, Yan Fang, Shen Zhang et al.· Advancement of science· 0 citations
A novel gut-liver axis is revealed in MASLD pathogenesis, demonstrating that Cur alleviates hepatic steatosis by targeting the microbiota-KYN-AHR-H3K27ac-Cebpb epigenetic axis, positioning Cur supplementation and KYN modulation as promising therapeutic strategies for MASLD intervention.
Yong Zhu, Jin-Hu Ma, Dan-Hong Wang et al.· Molecular Biomedicine· 0 citations
This narrative review explores the mechanistic pathways through which an altered gut microbiome contributes to MASLD, by specifically emphasizing intestinal barrier disruption, endotoxemia, altered bile acid metabolism, and SCFA imbalance.
Shweta Sharma, Arun Pachauri, Harsha Nagar et al.· Frontiers in Systems Biology· 0 citations
ABSTRACT Tilianin (Til), a flavonoid from Dracocephalum moldavica L. and Agastache species, exerts potent anti‐atherosclerotic effects via gut microbiota‐mediated mechanisms. In atherosclerotic mice, Til dose‐dependently reduced plaque burden and enhanced plaque stability by reducing necrotic cores and increasing colla...
Xu-Li Ruan, Ru-Yue Liu, Wen-Jiang Cao et al.· MedComm· 0 citations
ABSTRACT With dysregulation of the gut microbiota and its metabolic byproducts playing a pivotal role in inflammatory bowel disease (IBD) pathogenesis. Baitouweng Tang (BTWT), a traditional herbal formulation, has long been employed to treat gastrointestinal disorders and shows promising potential in the management of...
Chun Niu, Yong-Li Hua, Jian-Guo Kang et al.· Food Science & Nutrition· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is closely
associated with metabolic disorders such as obesity, insulin resistance, and dyslipidemia. Its prevalence continues to increase, and current
management strategies rely primarily on lifestyl...
K. Jončić Savić, A. Teofilović, M. Vratarić et al.· Zbornik radova· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.